All In Biotech

Drug Trial Radar · NCT07399067

A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof-of-Concept Study to Evaluate the Efficacy and Safety of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Feb 6, 2026

Primary completion

Mar 23, 2027

Study completion May 27, 2027

Sponsor

Sponsor type
Industry
First posted
Feb 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this Phase 2 study is to evaluate the efficacy and safety of IBI3002 in patients with moderate to severe Atopic Dermatitis (AD).

Conditions

  • Atopic Dermatitis

Interventions

  • IBI3002Drug

    IBI3002 will be administered subcutaneously at the assigned dose level and dosing interval.

  • PlaceboDrug

    Matched placebo will be administered subcutaneously at the same schedule as IBI3002.

  • DupilumabDrug

    Dupilumab 300mg Q2w, with a loading dose of 600mg, will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change from baseline in the Eczema Area and Severity Index (EASI) score at Week 16Time frame: Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China-japan Friendship Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.